Higher Adoption rates of Customized Medicines
The U.S. injectable compounding pharmacy market provides dosages and formulations tailored precisely to an individual's needs. Custom-made therapies are particularly beneficial for patients with complex medical conditions that cannot be treated with commercially available medications. The global pharmaceutical industry has witnessed substantial growth in recent years, however, medications are often not available in the required dosage, form, or combination needed by patients. This has increased the demand for specialized compounding pharmacies to create customized medications.
The global U.S. injectable compounding pharmacy market is estimated to be valued at US$ 1517.34 Mn in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The higher adoption rates of customized medicines formulated by compounding pharmacies are expected to drive the growth of the U.S. injectable compounding pharmacy market over the forecast period. Customized medications help many chronic disease and cancer patients manage their conditions more effectively by offering therapies tailored to their individual needs. Compounded drugs are also increasingly preferred over commercial drugs for pediatric patients who often need lower strengths or alternate dosage forms not commercially available. Growing geriatric population suffering from multiple chronic conditions also contributes to market growth. However, lack of standard manufacturing practices and absence of clinical data compared to FDA approved drugs are some challenges faced by compounding pharmacies. Additionally, pricing pressures may hamper market revenue growth.
SWOT Analysis:
- Strength: The U.S. injectable compounding pharmacy market has gained immense traction over recent years. The growing demand for tailored medication dosages and formulations is driving significant investments in advanced compounding facilities and equipment. Many players have established sterility testing labs and expanded their product portfolios to address underserved patient populations.
- Weakness: stringent regulatory landscape poses challenges for compounders and prescribers. The complexities involved in complying with cGMP guidelines increases operational costs. Furthermore, reimbursement issues continue to limit the uptake of certain compounded medications.
- Opportunity: Increasing prevalence of chronic diseases creates new demand. Tailored therapy options help optimize treatment outcomes. Rapidly aging population will drive the need for individualized doses. Moreover, the shift towards value-based care rewards higher efficacy therapies produced by compounders.
- Threats: Stringent federal and state regulatory changes threaten existing business models. Failure to comply can trigger recalls or facility shutdowns. Larger pharmaceutical companies vigorously defend branded drugs threatening substitutability with compounded alternatives. Network restrictions also limit prescriber access and patient reimbursement.
Key Takeaways:
The Global U.S. Injectable Compounding Pharmacy Market Demand is expected to witness high growth over the forecast period driven by favorable reimbursement policies and greater preference for customized medications. The global U.S. Injectable Compounding Pharmacy Market is estimated to be valued at US$ 1517.34 Mn in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023 to 2030.
Regional analysis: The U.S. currently accounts for the largest share of the global U.S. injectable compounding pharmacy market and is expected to maintain dominance through 2030. Favorable regulatory guidelines and adoption of advanced compounding technologies have supported market growth. However, Asia Pacific is slated to witness the fastest CAGR over the forecast period. This can be attributed to improving access to healthcare insurance, growing medical tourism industry, and rising prevalence of chronic diseases in densely populated countries of China and India.
Key players: Key players operating in the U.S. injectable compounding pharmacy market are Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd’s Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding Services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., SCA Pharma, and Vertisis Custom Pharmacy.
Explore more information on this topic, Please visit -